Quantum BioPharma adds Terry Lynch to its board

TORONTO - Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company currently trading at $6.95, announced today the appointment of Terry Lynch to its board of directors, succeeding Dr. Sanjiv Chopra, who has resigned but will continue to serve as an advisor to the company. According to InvestingPro data, the company’s stock has shown strong momentum with an 80% return over the past six months, despite trading near its Fair Value.

Terry Lynch, recognized for his advocacy against market manipulation through his non-profit Save Canadian Mining, brings a wealth of experience as a seasoned executive and board member. He is currently the CEO of Power Metallic Mines Inc. (TSXV: PNPN), which recently secured a significant financing round. Lynch also co-founded Cardiol Therapeutics and advises bionxt solutions, both operating in the biotech sector. His appointment comes at a crucial time, with Quantum BioPharma’s earnings report due on April 3rd.

Quantum BioPharma’s CEO, Zeeshan Saeed, expressed confidence in Lynch’s appointment, citing his fundraising expertise, biotech investment knowledge, and understanding of stock market dynamics as valuable assets for the company’s future endeavors.

In conjunction with his board appointment, Lynch has been granted 50,000 stock options to acquire Class B Shares at an exercise price of C$9.90 each, expiring on March 26, 2027, as part of the company’s equity incentive plan.

Quantum BioPharma specializes in developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, intended to prevent and reverse myelin degradation in multiple sclerosis. Furthermore, Quantum BioPharma maintains a 25.71% ownership stake in Celly Nutrition, the spin-off company of its OTC product unbuzzd™, and retains full rights to develop pharmaceutical and medical alternatives. InvestingPro analysis reveals the company maintains a healthy financial position with a current ratio of 3.76 and more cash than debt on its balance sheet. Discover 10 more exclusive InvestingPro Tips about QNTM’s financial health and growth prospects.

The company also manages strategic investments through its subsidiary, FSD Strategic Investments Inc., focusing on loans secured by property.

This news release is based on a press release statement and contains forward-looking information that involves risks and uncertainties. Quantum BioPharma has cautioned that its expectations regarding future events may differ from actual outcomes and encourages readers to consult additional company disclosures for a more comprehensive understanding of potential risks. For detailed financial analysis and real-time updates, investors can access comprehensive metrics and expert insights through InvestingPro.

In other recent news, Quantum BioPharma Ltd. has expanded its cryptocurrency holdings by purchasing an additional $1 million in Bitcoin and other digital currencies, doubling its investment to $2 million. This move is part of the company’s strategy to leverage cryptocurrencies for potential returns and as a hedge against the Canadian dollar. Additionally, Celly Nutrition Corporation, in which Quantum BioPharma holds a 25.71% stake, is targeting an initial public offering (IPO) on a major U.S. exchange with plans to raise up to $10 million USD in capital. The capital raise, contingent on regulatory approvals, will be managed by a New York investment bank.

Quantum BioPharma has also announced its dual listing on Upstream, a global securities trading app, to broaden its investor reach beyond current listings on the Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges. The dual listing aims to enhance liquidity and accessibility for international investors, although U.S. persons are restricted from trading on Upstream. The company continues to focus on developing treatments for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, targeting multiple sclerosis. Quantum BioPharma also benefits from a royalty payment structure with Celly Nutrition, receiving 7% royalties from sales of the unbuzzd product until a total of $250 million is reached, after which the royalty decreases to 3%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.